Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain-gastroesophageal axis
- PMID: 11447009
- DOI: 10.1152/ajpgi.2001.281.2.G311
Receptors and transmission in the brain-gut axis: potential for novel therapies. IV. GABA(B) receptors in the brain-gastroesophageal axis
Abstract
GABA(B) receptors are inhibitory G protein-coupled receptors that are commonly associated with presynaptic inhibition of transmitter release in the central nervous system. In the brain-gastroesophageal axis, a role has recently been demonstrated for GABA(B) receptors on extrinsic afferent endings within the stomach and esophagus, where they reduce mechanosensitivity. This action is compounded by inhibition of communication centrally from these afferents in the brain stem and within central circuits. There is a final peripheral action on the motor pathway where GABA(B) receptors reduce output of acetylcholine from vagal preganglionic motoneurons. These potent, multiple actions of GABA(B) receptors may have therapeutic benefit by reducing the triggering of transient lower esophageal relaxations, which are the major cause of gastroesophageal reflux. An important clinical application is therefore emerging for this recent discovery.
Similar articles
-
Peripheral versus central modulation of gastric vagal pathways by metabotropic glutamate receptor 5.Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G501-11. doi: 10.1152/ajpgi.00353.2006. Epub 2006 Oct 19. Am J Physiol Gastrointest Liver Physiol. 2007. PMID: 17053158
-
GABA(B) receptors inhibit mechanosensitivity of primary afferent endings.J Neurosci. 1999 Oct 1;19(19):8597-602. doi: 10.1523/JNEUROSCI.19-19-08597.1999. J Neurosci. 1999. PMID: 10493759 Free PMC article.
-
Vagal neurotransmission to the ferret lower oesophageal sphincter: inhibition via GABA(B) receptors.Br J Pharmacol. 2000 Oct;131(3):624-30. doi: 10.1038/sj.bjp.0703602. Br J Pharmacol. 2000. PMID: 11015316 Free PMC article.
-
Central control of lower esophageal sphincter relaxation.Am J Med. 2000 Mar 6;108 Suppl 4a:90S-98S. doi: 10.1016/s0002-9343(99)00345-9. Am J Med. 2000. PMID: 10718459 Review.
-
Roles of gastro-oesophageal afferents in the mechanisms and symptoms of reflux disease.Handb Exp Pharmacol. 2009;(194):227-57. doi: 10.1007/978-3-540-79090-7_7. Handb Exp Pharmacol. 2009. PMID: 19655109 Review.
Cited by
-
Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.BMC Gastroenterol. 2014 Nov 18;14:188. doi: 10.1186/1471-230X-14-188. BMC Gastroenterol. 2014. PMID: 25407279 Free PMC article. Clinical Trial.
-
Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.Drugs. 2004;64(4):347-61. doi: 10.2165/00003495-200464040-00001. Drugs. 2004. PMID: 14969571 Review.
-
Refractory gastroesophageal reflux disease.Gastroenterol Rep (Oxf). 2015 Feb;3(1):41-53. doi: 10.1093/gastro/gou061. Epub 2014 Sep 30. Gastroenterol Rep (Oxf). 2015. PMID: 25274499 Free PMC article. Review.
-
Small bowel review: Normal physiology, part 2.Dig Dis Sci. 2003 Aug;48(8):1565-81. doi: 10.1023/a:1024724109128. Dig Dis Sci. 2003. PMID: 12924652 Review. No abstract available.
-
Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease.World J Gastroenterol. 2013 Oct 21;19(39):6529-35. doi: 10.3748/wjg.v19.i39.6529. World J Gastroenterol. 2013. PMID: 24151377 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources